IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat

Carcinogenesis

Volumn 25, Issue 3, 2004, Pages 389-397

  Nakaji, Miyuki ^a   Yano, Yoshihiko ^a   Ninomiya, Toshiaki ^a   Seo, Yasushi ^a   Hamano, Kenichi ^a   Yoon, Seitetsu ^a   Kasuga, Masato ^a   Teramoto, Tadahisa ^b   Hayashi, Yoshitake ^a   Yokozaki, Hiroshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA ACTIN; CELL NUCLEUS ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; DIETHYLNITROSAMINE; N (2 FLUORENYL)ACETAMIDE; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARCINOMA, HEPATOCELLULAR; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; LIVER; MALE; PRECANCEROUS CONDITIONS; RATS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12144289725     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh028     Document Type: Article

References (45)

1. Schrimacher,P., Rogler,C.E. and Dienes,H.P. (1993) Current pathogenetic and molecular concepts in viral liver carcinogenesis. Virch. Arch. B Cell Pathol., 63, 71-89.
2. Negro,F., Papotti,M., Taraglio,S., Rubbia,B.L., Giostra,E., Pacchioni,D., Rizzetto,M. and Hadengue,A. (1997) Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. J. Viral. Hepat., 4, 93-98.
3. Yoshida,H., Shiratori,Y., Moriyama,M. et al. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med., 131, 174-181.
4. Nishiguchi,S., Kuroki,T., Nakatani,S., Morimoto,H., Takeda,T., Nakajima,S., Shiomi,S., Seki,S., Kobayashi,K. and Otani,S. (1995) Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346, 1051-1055.
5. Ikeda,K., Saitoh,S., Suzuki,Y. et al. (1998) Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer, 82, 827-835.
6. Pfeffer,L.M. (1997) Biologic activities of natural and synthetic type 1 interferons. Semin. Oncol., 24, S9-63-S9-69.
7. Solt,D.B., Medline,A. and Farber,E. (1977) Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am. J. Pathol., 88, 595-618.
8. Van Gijssel,H.E., Ohlson,L.C., Torndal,U.B., Mulder,G.J., Eriksson,L.C., Porsch-Hallstrom,I. and Meerman,J.H. (2000) Loss of nuclear p53 protein in preneoplastic rat hepatocytes is accompanied by Mdm2 and Bcl-2 overexpression and by defective response to DNA damage in vivo. Hepatology, 32, 701-710.
9. Sillins,I., Finnberg,N., Ståhl,A., Högberg,J. and Stenius,U. (2001) Reduced ATM kinase activity and an attenuated p53 response to DNA damage in carcinogen-induced preneoplastic hepatic lesions in the rat. Carcinogenesis, 22, 2023-2031.
10. Van Gijssel,H.E., Maassen,C.B., Mulder,G.J. and Meerman,J.H. (1997) P53 protein expression by hepatocarcinogenesis in the rat liver and its potential role in mitoinhibition of normal hepatocytes as a mechanism of hepatic tumor promotion. Carcinogenesis, 18, 1027-1033.
11. Lennartsson,P., Högberg,J. and Stenius,U. (1998) Wild-type p53 expression in liver tissue and in enzyme altered foci: An in vivo investigation on diethylnitrosoamine-treated rats. Carcinogenesis, 19, 1231-1237.
12. Carson,D.A. and Lois,A. (1995) Cancer progression and p53. Lancet, 346, 1009-1011.
13. Kern,S.E., Kinzler,K.W., Bruskin,A., Jarosz,D., Friedman,P., Prives,C. and Vogelstein,B. (1991) Nucleotide, genome identification of p53 as a sequence-specific DNA-binding protein. Science, 252, 1708-1711.
14. Xiong,Y., Hannon,G.J., Zhang,H., Casso,D., Kobayashi,R. and Beach,D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature. 366, 701-704.
15. Nardone,G., Staibano,S., Rocco,A. et al. (1999) Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA safety and oncogene expression in patients with chronic gastritis. Gut, 44, 789-799.
16. Feitelson,M.A., Sun,B., Satiroglu Tufan,N.L., Liu,J., Pan,J. and Lian,Z. (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene, 21, 2593-2604.
17. Farber,E. (1996) The step-by-step development of epithelial cancer: From phenotype to genotype. Adv. Cancer Res., 70, 21-48.
18. El-deiru,W.S., Harper,J.W., O'Connor,P.M. et al. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
19. Scott,MT., Morrice,N. and Ball,K.L. (2000) Reversible phosphorylation at the C-terminal regulatory domain of p21 (Waf1/Cip1) modulates proliferating cell nuclear antigen binding. J. Biol. Chem., 14, 11529-11537.
20. Cayrol,C., Knibiehler,M. and Ducommun,B. (1998) p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene, 22, 311-320.
21. Cohen,S.M. and Ellewein,L.B. (1990) Cell proliferation in carcinogenesis. Science 31, 1007-1011.
22. Hui,A.M., Kanai,Y., Sakamoto,M. Tsuda,H. and Hirohashi,S. (1997) Reduced p21 (WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology, 25, 575-579.
23. Hsu,I.C., Metcalf,R.A., Sun,T., Welsh,J.A., Wang,N.J. and Harris,C.C. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
24. Campbell,H.A., Pitot,H.C., Potter,V.R. and Laishes,B.A. (1982) Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res., 42, 465-472.
25. Squire,R.A. and Levitt,M.H. (1975) Report of a workshop on classification of specific hepatocellular lesions in rats. Cancer Res., 35, 3214-3223.
26. Kotoh,T., Dhar,D.K., Masunaga,R., Tabara,H., Tachibana,M., Kubota,H., Kohno,H. and Nagasue,N. (1999) Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery, 125, 536-544.
27. Satoh,K., Hatayama,I., Suchida,S. and Sato,K. (1991) Biochemical characteristics of a preneoplastic marker enzyme glutathione-S-transferase P-form (7-7). Arch. Biochem. Biophys., 285, 312-316.
28. Stenius,U. and Högberg,J. (1995) GST-P positive hepatocytes isolated from rats bearing enzyme-altered foci show no signs of p53 protein induction and replicate even when their DNA contains strand breaks. Carcinogenesis, 16, 1683-1686.
29. van Gijssel,H.E., Stenius,U., Mulder,G.J. and Meerman,J.H.N. (2000) Lack of p53 protein expression in preneoplastic rat hepatocytes in vitro after exposure to N-acetoxy-acetylaminofluorene, X-rays or a proteasome inhibitor. Eur. J. Cancer, 36, 106-112.
30. Finnberg,N., Stenius,U. and Högberg,J. (2000) Xenobiotics modulate the p53 response to DNA damage in preneoplastic enzyme-altered foci in rat liver; effects of dietylnitrosamine and Phenobarbital. Toxicol. Sci., 54, 95-103.
31. Huo, TI., Wand,X.W., Forgues,M., Wu,C.G., Spillare,E.A., Giannini,C., Brechot,C. and Harris,C.C. (2001) Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53 induced apoptosis. Oncogene, 20, 3620-3628.
32. Ahn,J.Y., Chung,E.Y., Kwun,H.J. and Jang,K.L. (2001) Transcriptional repression of p21 (waf1) promoter by hepatitis B virus X protein via a p53-independent pathway. Gene, 275, 163-168.
33. Ray,R.B., Steele,R., Meyer,K. and Ray,R. (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem., 272, 10983-10986.
34. Ray,R.B., Steele,R., Meyer,K. and Ray,R. (1998) Hepatitis C virus core protein represses p21 WAF1/Cip1/Sid1 promoter activity. Gene, 208, 331-336.
35. de Lujan Alvarez,M., Cerliani,J.P., Monti,J., Carnovale,C., Ronco,M.T., Pisani,G., Lugano,M.C. and Carrillo,M.C. (2002) The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology, 35, 824-833.
36. Murphy,D., Detjen, KM., Welzel,M., Wiedenmann,B. and Rosewicz,S. (2001) Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology, 33, 346-356.
37. Grander,D., Xu,B. and Einhorn,S. (1993) Cytotoxic effect of interferon on primary malignant tumor cells. Studies in various malignancies. Eur. J. Cancer, 29A, 1940-3.
38. Kimchi,A. (1992) Cytokine trigger molecular pathways that control cell cycle arrest. J. Cell. Biochem., 50, 1-9.
39. Sangfelt,O., Erickson,W., Castro,J., Heiden,T., Gustafsson,A., Einhorn,S. and Grandér,D. (1999) Molecular mechanisms underlying interferon-α-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene, 18, 2798-2810.
40. Rewms,S., Subramaniam,M. and Howard,M.J. (1997) A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type 1 interferons. J. Interferon Cytokine Res., 17, 11-15.
41. Wang,C.H., Tsao,Y.P., Chen,H.J., Chen,H.L., Wang,H.W. and Chen,S.L. (2000) Transcriptional repression of p21 ((Waf1/Cip1/Sdi1)) gene by c-jun through Sp1 site. Biochem. Biophys. Res. Commun., 270, 303-310.
42. Michieli,P., Chedid,M., Lin,D., Pierce,J.H., Mercer,W.E. and Givol,D. (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54, 3391-3395.
43. Tanaka,N., Ishihara,M., Lamphier, MS., Nozawa,H., Matsuyama,T., Mak,T.W., Aizawa,S., Tokino,T., Oren,M. and Taniguchi,T. (1996) Cooperation of the tumor-suppressors IRF-1 and p53 in response to DNA damage. Nature, 382, 816-818.
44. Tada,S., Saito,H., Tsunematsu,S., Ebinuma,H., Wakabayashi,K., Masuda,T. and Ishii,H. (1998) Interferon regulatory factor-1 gene abnormality and loss of growth inhibitory effect of interferon-α in human hepatoma cell lines. Int. J. Oncol., 13, 1207-1216.
45. Takayama,T., Makuuchi,M., Hirohashi,S., Sakamoto,M., Okazaki,N., Takayasu,K., Kosuge,T., Motoo,Y., Yamazaki,S. and Hasegawa,H. (1990) Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet, 336, 1150-1153.